13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001055951
Total reported value
$5.4B
$5.4B
112 檔
24.5%
The Q1 2024 SEC filing reveals that Orbimed Advisors LLC held a total portfolio value of $5.4B, covering 112 public equity positions.
Orbimed Advisors LLC executed strategic sector rebalancing during Q1 2024, establishing 9 new positions while fully exiting 10 holdings and trimming 14 positions.
In terms of portfolio concentration, the top 5 core holdings (including SVA, LLY, EWTX) accounted for 24.5% of total reported equity market value during Q1 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SVA | Sinovac Biotech Ltd. | Stock-Other | 6.23% | +3.06% | — | |
| 2 | LLY | Eli Lilly & Co | Stock-Healthcare | 5.14% | +1.30% | -1.26% | |
| 3 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 5.02% | +1.73% | +3.12% | |
| 4 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.11% | -1.88% | -1.02% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.60% | -0.80% | -1.18% | |
| 6 | BIIB | Biogen Inc | Stock-Healthcare | 3.56% | +0.02% | +8.86% | |
| 7 | MRK | Merck & Co. Inc. | Stock-Healthcare | 3.18% | -0.05% | +24.74% | |
| 8 | JANX | Janux Therapeutics Inc | Stock-Other | 2.95% | -0.13% | +28.86% | |
| 9 | ELVN | Enliven Therapeutics Inc | Stock-Other | 2.90% | +0.02% | — | |
| 10 | THC | Tenet Healthcare CORP | Stock-Healthcare | 2.26% | — | -4.17% | |
| 11 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 2.05% | — | -18.64% | |
| 12 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 1.95% | — | +5.73% | |
| 13 | IRON | Disc Medicine Inc | Stock-Other | 1.94% | -0.91% | — | |
| 14 | SYK | Stryker CORP | Stock-Healthcare | 1.76% | -0.30% | — | |
| 15 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 1.73% | -0.12% | — | |
| 16 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 1.65% | — | — | |
| 17 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 1.60% | — | -2.51% | |
| 18 | ELV | Elevance Health Inc | Stock-Healthcare | 1.60% | +0.21% | +18.80% | |
| 19 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 1.57% | — | — | |
| 20 | EVH | Evolent Health Inc - A | Stock-Other | 1.56% | — | -5.13% | |
| 21 | APLSUSD | Apellis Pharmaceuticals Inc | Stock-Other | 1.56% | — | +56.99% | |
| 22 | SWTXUSD | Springworks Therapeutics Inc | Stock-Other | 1.54% | — | -46.97% | |
| 23 | KROS | Keros Therapeutics Inc | Stock-Other | 1.54% | -0.02% | — | |
| 24 | NTRA | Natera Inc | Stock-Healthcare | 1.51% | +0.26% | -5.77% | |
| 25 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.41% | +0.38% | -8.21% | |
| 26 | PCVX | Vaxcyte Inc | Stock-Other | 1.33% | — | -7.54% | |
| 27 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 1.19% | -0.04% | -16.93% | |
| 28 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.16% | — | -15.79% | |
| 29 | ARGX | Argenx Se - Adr | Stock-Healthcare | 1.09% | -0.44% | +79.20% | |
| 30 | ICLR | ICON Public Limited Company | Stock-Healthcare | 1.07% | — | +31.69% | |
| 31 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 1.07% | — | -18.52% | |
| 32 | SIBN | Si-bone Inc | Stock-Other | 1.03% | — | +49.38% | |
| 33 | VRNA | Verona Pharma PLC - Adr | Stock-Other | 1.00% | — | -10.05% | |
| 34 | ✓ | Third Harmonic Bio Inc | Stock-Other | 1.00% | — | — | |
| 35 | AVBP | Arrivent Biopharma Inc | Stock-Other | 0.99% | +0.53% | — | |
| 36 | NPCE | Neuropace Inc | Stock-Other | 0.97% | -0.11% | — | |
| 37 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.95% | +0.60% | — | |
| 38 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 0.94% | — | -29.97% | |
| 39 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.92% | — | — | |
| 40 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.88% | +0.04% | NEW | |
| 41 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.87% | — | -43.74% | |
| 42 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.81% | -1.03% | — | |
| 43 | GERN | Geron CORP | Stock-Other | 0.78% | — | +2558.48% | |
| 44 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.76% | +0.17% | — | |
| 45 | QTTB | Q32 Bio Inc | Stock-Other | 0.70% | +0.68% | — | |
| 46 | ESPR | Esperion Therapeutics Inc | Stock-Other | 0.67% | -0.59% | EXIT | |
| 47 | ✓ | Ikena Oncology Inc | Stock-Other | 0.66% | -0.45% | EXIT | |
| 48 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 0.63% | +1.33% | NEW | |
| 49 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.56% | +0.11% | +31.34% | |
| 50 | ALXO | Alx Oncology Holdings Inc | Stock-Other | 0.56% | -0.01% | -12.18% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | JANX | Janux Therapeutics Inc | +2.2% | +28.86% | Add |
| 2 | EWTX | Edgewise Therapeutics Inc | +1.8% | +3.12% | Add |
| 3 | NVLSEUR | Alpine Immune Sciences Inc | +1% | +5.73% | Add |
| 4 | AVBP | Arrivent Biopharma Inc | +1% | NEW | New buy |
| 5 | LLY | Eli Lilly & Co | +0.9% | -1.26% | Trim |
| 6 | MRK | Merck & Co. Inc. | +0.9% | +24.74% | Add |
| 7 | CYTK | Cytokinetics Inc | +0.9% | NEW | New buy |
| 8 | GERN | Geron CORP | +0.8% | +2558.48% | Add |
| 9 | SPRY | Ars Pharmaceuticals Inc | +0.7% | — | Unchanged |
| 10 | QTTB | Q32 Bio Inc | +0.7% | NEW | New buy |
| 11 | ESPR | Esperion Therapeutics Inc | +0.7% | NEW | New buy |
| 12 | KROS | Keros Therapeutics Inc | +0.5% | — | Unchanged |
| 13 | PRAX | Praxis Precision Medicines I | +0.5% | NEW | New buy |
| 14 | MLYS | Mineralys Therapeutics Inc | +0.5% | NEW | New buy |
| 15 | APLSUSD | Apellis Pharmaceuticals Inc | +0.5% | +56.99% | Add |
| 16 | RNAGBP | Avidity Biosciences Inc | +0.5% | NEW | New buy |
| 17 | ARGX | Argenx Se - Adr | +0.5% | +79.20% | Add |
| 18 | ELVN | Enliven Therapeutics Inc | +0.4% | — | Unchanged |
| 19 | THC | Tenet Healthcare CORP | +0.4% | -4.17% | Trim |
| 20 | DYN | Dyne Therapeutics Inc | +0.4% | NEW | New buy |
| 21 | NTRA | Natera Inc | +0.3% | -5.77% | Trim |
| 22 | ICLR | ICON Public Limited Company | +0.3% | +31.69% | Add |
| 23 | SRPT | Sarepta Therapeutics Inc | +0.3% | — | Unchanged |
| 24 | HRTX | Heron Therapeutics Inc | +0.3% | +70.56% | Add |
| 25 | BSX | Boston Scientific CORP | +0.3% | -1.02% | Trim |
| 26 | ELV | Elevance Health Inc | +0.3% | +18.80% | Add |
| 27 | ISRG | Intuitive Surgical Inc | +0.2% | -1.18% | Trim |
| 28 | TYRA | Tyra Biosciences Inc | +0.2% | NEW | New buy |
| 29 | MORFUSD | Morphic Holding Inc | +0.2% | +104.28% | Add |
| 30 | APGE | Apogee Therapeutics Inc | +0.2% | -43.74% | Trim |
| 31 | SYK | Stryker CORP | +0.2% | — | Unchanged |
| 32 | PFE | Pfizer Inc | -0.3% | EXIT | Sold out |
| 33 | ALNY | Alnylam Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 34 | ALXO | Alx Oncology Holdings Inc | -0.4% | -12.18% | Trim |
| 35 | AMGN | Amgen Inc | -0.4% | -50.20% | Trim |
| 36 | SRRK | Scholar Rock Holding CORP | -0.4% | -15.79% | Trim |
| 37 | VRTX | Vertex Pharmaceuticals Inc | -0.5% | -29.97% | Trim |
| 38 | IONS | Ionis Pharmaceuticals Inc | -0.5% | -2.51% | Trim |
| 39 | VRNA | Verona Pharma PLC - Adr | -0.5% | -10.05% | Trim |
| 40 | ✓ | Fusion Pharmaceuticals Inc | -0.6% | EXIT | Sold out |
| 41 | BIIB | Biogen Inc | -0.7% | +8.86% | Add |
| 42 | IOVA | Iovance Biotherapeutics Inc | -0.8% | EXIT | Sold out |
| 43 | SWTXUSD | Springworks Therapeutics Inc | -0.8% | -46.97% | Trim |
| 44 | BMRN | Biomarin Pharmaceutical Inc | -1% | -18.64% | Trim |
| 45 | HUM | Humana Inc | -1% | EXIT | Sold out |
| 46 | RCM1USD | R1 Rcm Inc | -1% | EXIT | Sold out |
| 47 | ✓ | Theseus Pharmaceuticals Inc | -1.4% | EXIT | Sold out |
| 48 | UTHR | United Therapeutics CORP | -1.7% | EXIT | Sold out |
| 49 | ✓ | Gracell Biotechnologies-adr | -1.9% | EXIT | Sold out |
| 50 | ✓ | Rayzebio Inc | -2.9% | EXIT | Sold out |
According to official SEC Form 13F filings, Orbimed Advisors LLC reported a total U.S. public equity portfolio value of $5.4B across 112 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AVBP
市值: $54.1M
Top Position Liquidated / Trimmed
RAYZEBIO INC
前期市值: $147.0M
During Q1 2024, Orbimed Advisors LLC's top holdings by market value included SVA (6.2%)、LLY (5.1%)、EWTX (5.0%). The largest single position, SVA, represented 6.2% of total portfolio value.
In Q1 2024, Orbimed Advisors LLC made 45 total portfolio adjustments, initiating 9 new buys, adding to 12 positions, trimming 14 holdings, and fully liquidating 10 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.